Our survey also showed that, besides insulin, which is recommended by the recent consensus guidelines, centres show a preference for using DPP-4 inhibitors (61%), metformin (49%), and sulfonylureas/glinides (45%) over newer agents such as SGLT2 inhibitors (25%) and GLP-1 analogues (20%) to treat early post-transplant hyperglycaemia. The gene discussed is INS; the disease is Hyperglycemia.